Skip to content
Back to Blog
Bio
2026-05-118 min read13

KTL Advanced Biomaterial Commercialization Support Program Guide 2026

A comprehensive 2026 guide to KTL's KRW 28 billion Advanced Biomaterial Commercialization Support Program—covering staged support, eligibility, evaluation criteria, bonus point strategies, and how KITIM consulting maximizes selection success.

KITIM Consulting Team

Overview of the Advanced Biomaterial Commercialization Support Program

The Advanced Biomaterial Commercialization Support Program, organized by the Korea Testing Laboratory (KTL), is a flagship initiative aligned with the Ministry of Trade, Industry and Energy's Bioeconomy 2030 strategy. It aims to strengthen the global competitiveness of Korean SMEs in the biomaterial sector. In 2026, the program's budget has been expanded by approximately 25% to KRW 28 billion, supporting an estimated 80 to 100 companies with tailored, stage-specific assistance.

Policy Background and Direction

The global biomaterial market is projected to grow from USD 470 billion in 2025 to USD 780 billion by 2030, an annual growth rate of 10.7%. However, Korea's self-sufficiency rate in core biomaterials remains around 30%. The government has set 50% localization and KRW 1 trillion in import substitution as core targets for 2026.

Support Scope and Full Commercialization Pipeline

KTL focuses on companies at the pre-commercialization stage, distinguishing this program from traditional R&D initiatives.

Stage-by-Stage Support

  • Prototype Development: Pilot line access and up to KRW 150 million for 1–3 prototype iterations
  • Quality Evaluation and Testing: Free property, safety, and efficacy testing using KTL's infrastructure
  • Standardization and Certification: ISO 10993 (biocompatibility), ISO 13485, CE-MDR, FDA 510(k) certification consulting
  • Market Entry: Global buyer matching, up to KRW 30 million for international trade show participation, post-contract export support
  • Funding Scale

    Each selected company receives an average integrated support package of KRW 300–500 million, with 70% government funding and 30% company contribution (10% cash + 20% in-kind).

    Application Schedule and Eligibility

    2026 Timeline

  • First Call: Mid-March 2026 (30-day application window)
  • Second Call: Early July 2026 (30-day application window)
  • Evaluation and Agreement: Within 60 days after application deadline
  • Project Duration: 12 months from contract date (extendable up to 24 months)
  • Eligibility Requirements

  • Domestic SMEs or mid-sized enterprises (preference for startups under 7 years)
  • At least one registered or pending patent related to biomaterials
  • R&D expenditure of 3% or more of revenue in the last 3 years
  • Debt-to-equity ratio under 500%, credit rating BB- or above
  • Priority Sectors

  • Novel Biomaterials: Biodegradable plastics, biopolymers, natural extract materials
  • Medical Materials: Artificial organ materials, drug delivery systems (DDS), tissue engineering scaffolds
  • Eco-Friendly Biomaterials: Microbial-based chemicals, enzymatic materials, green bio chemicals
  • Key Points for Business Plan Writing

    Evaluation criteria allocate 35 points to technology, 30 to market viability, 25 to commercialization strategy, and 10 to corporate capability. Market viability and commercialization strategy carry significant weight, requiring a different approach from pure R&D proposals.

    Core Writing Strategies

  • Technology: Quantify advantages over existing materials (e.g., 20%+ performance gain, 30% cost reduction)
  • Market Viability: TAM-SAM-SOM analysis, 3-year revenue targets, attached Letters of Intent (LOIs) from key customers
  • Commercialization Strategy: Mass production roadmap, certification timeline, country-specific export plans
  • Bonus Point Strategy

    Up to 10 bonus points are available through patents (2 pts domestic / 3 pts PCT), existing certifications (2 pts ISO), export records (2 pts), female/youth CEOs (1 pt), and regional companies (2 pts).

    How KITIM Consulting Can Help

    KITIM is a specialized consulting firm with a 75%+ selection rate for KTL commercialization programs. We go beyond proposal writing, delivering an integrated roadmap aligned with KTL's testing and certification schedule.

    KITIM Services

  • Pre-Eligibility Diagnosis: Free 30-minute consultation to evaluate selection probability
  • Proposal Writing Support: 1:1 advisory by former evaluators with 3 rounds of revisions
  • Presentation Coaching: 2 mock presentations and 100 Q&A drills
  • Certification Roadmap: Integrated timeline management for ISO 13485, CE, FDA, and other global certifications
  • Post-Contract Management: Stage-based reporting and settlement support after agreement signing
  • Don't miss this pivotal opportunity in biomaterial commercialization. Partner with KITIM's expert consultants to win selection in the KTL Advanced Biomaterial Commercialization Program and accelerate your global market entry. Request your free consultation today for a customized strategic proposal.

    KTLAdvancedBiomaterialCommercializationMOTIEBioSME

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.